RxDoctor Payments Data

James Kelly, APRN

Family · Rocky Hill, CTNPI 1356365522

Payments from drug & device makers

$1,061in general payments, 2019–2025

Across 45 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$446
  • Axsome Therapeutics, Inc.$247
  • GSK$198
  • Lilly USA, LLC$45
  • Abbott$41
  • Amgen$25
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$1,061100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,061 in reported general payments places this provider in the 70th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$24,616
Medicare patients
124
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol56$68,978
MounjaroTirzepatide43$49,456
EliquisApixaban38$27,910
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$27,408
OzempicSemaglutide16$27,311
WegovySemaglutide12$16,249
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$9,401
Humalog Kwikpen U-100Insulin Lispro20$6,049
Insulin Lispro Kwikpen U-100Insulin Lispro14$4,491
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$2,390
Ultra-Fine Short Pen NeedlePen Needle, Diabetic13$1,309
Gabapentin66$1,248
Atorvastatin Calcium174$1,167
Omega-3 Acid Ethyl Esters14$1,129
Levothyroxine Sodium85$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$45$49,45643 claims
Novo NordiskOzempic, Wegovy$18$43,56028 claims
GSKTrelegy Ellipta$198$27,40823 claims
AbbVieSynthroid$446$59118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,596 family providers in Connecticut.

Other family in Rocky Hill

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →